Arcellx, Inc. (ACLX)
72.18
+3.24
(+4.69%)
USD |
NASDAQ |
Jan 20, 16:00
72.05
-0.12
(-0.17%)
After-Hours: 20:00
Arcellx EPS Diluted (Quarterly): -0.9858 for Sept. 30, 2025
EPS Diluted (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
EPS Diluted (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
EPS Diluted (Quarterly) Benchmarks
| Gilead Sciences, Inc. | 2.434 |
| Johnson & Johnson | 2.121 |
| Amicus Therapeutics, Inc. | 0.0558 |
| Relmada Therapeutics, Inc. | -0.304 |
| Invivyd, Inc. | -0.0615 |
EPS Diluted (Quarterly) Related Metrics
| Net Income (Quarterly) | -55.78M |
| Revenue (Quarterly) | 4.949M |
| Total Expenses (Quarterly) | 60.73M |
| Enterprise Value | 3.577B |
| Gross Profit Margin (Quarterly) | 62.76% |
| Profit Margin (Quarterly) | -1.13K% |
| Earnings Yield | -5.43% |
| Normalized Earnings Yield | -5.429 |